3
Announcements
Trials
Browse
Landscape
Phase
Phase 1
1
Status
Completed
1
Sponsor Class
INDUSTRY
1
Study Type
Interventional
1
Sponsor
Cancer Type
Thoracic
1
Gastrointestinal
1
Breast
1
Conditions
Pancreatic Neoplasms
2
Neoplasms
2
Carcinoma, Non-Small-Cell Lung
2
Triple Negative Breast Neoplasms
1
Thymoma
1
Ovarian Neoplasms
1
Mesothelioma
1
Medical Oncology
1
Lung Neoplasms
1
Cholangiocarcinoma
1
Interventions
pembrolizumab
2
Cyclophosphamide
2
Celecoxib
2
olaparib
1
isophosphamide mustard
1
fludarabine
1
entinostat
1
bosutinib
1
anetumab ravtansine
1
Pemetrexed
1
Imatinib Mesylate
1
Gemcitabine
1
FANG vaccine
1
Cisplatin
1
Date Range
30 days
90 days
1 year
All
Options
Has results
Has announcements
Clinical Trials
1 trials
Recent
Start date
Enrollment
Phase 1
×
Thymoma
×
anetumab ravtansine
×
Clear all
NCT03102320
2022-06-30
ARCS-Multi
Bayer
Phase 1
Completed
173 enrolled